[A case of recurrent pulmonary lymphoepithelioma-like carcinoma responding to treatment with CBDCA/paclitaxel combined chemotherapy].
A 57-year-old female underwent left lower lung lobectomy and was histologically diagnosed as having lymphoepithelioma-like carcinoma. One year and 2 months after surgery, pleural thickening was recognized, so she was administered 4 courses of CBDCA/PTX combined chemotherapy. Toxicity associated with the chemotherapy was very mild. Pleural thickening and effusion disappeared after treatment, so this case was judged to be a complete response. She suffered from left chest pain before chemotherapy, which later lessened. She was thus able to stop taking NSAIDs. Because primary pulmonary lymphoepithelioma-like carcinoma is a rare tumor, there is no standard chemotherapy treatment. CBDCA/PTX combined chemotherapy is effective for pulmonary lymphoepithelioma-like carcinoma and shows good tolerability and improves QOL.
Abe
Tetsuya
T
Division of Respiratory Medicine, Niigata University Graduate School of Medical and Dental Sciences.
Tanabe
Yoshinari
Y
Watanabe
Satoshi
S
Fujita
Nanae
N
Matsumoto
Naoya
N
Moriyama
Hiroshi
H
Kagamu
Hiroshi
H
Yokota
Tatsuya
T
Yoshizawa
Hirohisa
H
Gejyo
Fumitake
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008197:Lymph Node Excision; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011013:Pneumonectomy
D016190:Carboplatin; D017239:Paclitaxel